RasQ: Emotion, Mood and Executive Function in Parkinson's Disease (PD)
Study Details
Study Description
Brief Summary
The current study aims to assess the effect of an 8 week Azilect treatment (as adjunct therapy to levodopa) on affect perception and emotional expressiveness in a double-blind placebo-controlled study.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Parkinson's disease (PD) is associated with a range of cognitive impairments, most notably deficits of higher order cognitive control mechanisms referred to as "executive dysfunction". These problems have consistently been related to dysfunction of fronto-striatal circuitry (summary see Stocchi & Brusa, 2000). Executive function impairments may already be present in early stages of PD (Uekermann et al., 2004) and their severity may be exacerbated by affective changes such as depression (Uekermann et al., 2003). In addition to cognitive problems, PD patients frequently suffer from mood changes, in particular apathy (Kirsch-Darrow et al., 2006) and from affect processing impairments, relating to both the ability to decode the affective state of other people on the basis of facial expressions or prosody and to the ability to adequately express the patients' own emotions (e.g. Breitenstein et al., 1998; Zgaljardic et al., 2003, Pell & Leonard, 2005). The capacity for emotion perception was found to be linked to the severity of executive dysfunction; affective and cognitive changes are thus not independent, at least in patients with moderate PD (Breitenstein et al., 2001).
In a recent drug monitoring study by Lundbeck GmbH/TEVA Pharma GmbH based on a small group of PD patients (n=29), introduction of Azilect (Rasagiline) therapy was associated with a significant improvement of PD patients' emotional expressiveness (e.g. facial expression, gestures, voice intonation) over an 8 week observation period. Significant improvements were observed for self-ratings of emotional expressiveness as well as ratings by physicians and relatives. The lack of a placebo-control group, however, does not allow any firm conclusions with regard to the specificity of these effects.
Intact affect recognition and an adequate ability to express emotions are of critical importance for social interaction. The therapeutic efficacy of drug treatment on non-motor symptoms in PD has so far only rarely been addressed. The documentation of a beneficial effect of Azilect on emotional processing would be of great relevance for the quality of life of PD patients and greatly enhance their ability to participate in social life.
The addition of a placebo control group is critical for the assessment of the specificity of the expected beneficial effects of Azilect.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo Placebo 1 Tbl per day, 12 week (84 days) duration |
Drug: Placebo
Placebo 1 Tbl per day, 12 week (84 days) duration
|
| Active Comparator: Rasagiline Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration |
Drug: Rasagiline
Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Assess the effect of Azilect on mood, recognition of facial and vocal affect and emotional expressiveness [12 weeks]
Discrimination Faces Discrimination Affect Affect Naming -Faces Discrimination linguistic prosody Discrimination affective prosody Affect naming -congruent and incongruent affective prosody Visual Analogue Scales of emotional expressiveness Rating by study physician and relative Self-rating by patient Assessment of executive function Working Memory (n-back task, digit backward) Verbal Fluency (Regensburger Wortflüssigkeitstest) Beck Depression Inventary (BDI) Apathie Evaluations-Skala (AES) Social Activity Scale - self assessment PDQ-39- self-assessment
Secondary Outcome Measures
- Effect on motor function in PD [12 weeks]
Unified Parkinson's Disease Rating Scale
Eligibility Criteria
Criteria
Inclusion Criteria:
-
idiopathic PD
-
age range 30-75 yrs, HY I-III
-
stable medication for at least 4 weeks prior to baseline
-
Native speakers (German)
-
signing of informed consent form
Exclusion Criteria:
-
clinically significant depression (BDI>13)
-
freezing, pronounced fluctuations
-
other neurological or psychiatric disorders
-
dementia (MMSE<25)
-
treatment with the MAO-B-inhibitor Selegiline, antidepressants
-
any contraindication according to SmPC
-
participation in another interventional study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | St. Josef Hospital | Bochum | Nordrhein-Westfalen | Germany | 44791 |
Sponsors and Collaborators
- St. Josef Hospital Bochum
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology. 1998 May;50(5):1327-31.
- Roca M, Torralva T, Gleichgerrcht E, Chade A, Arévalo GG, Gershanik O, Manes F. Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cogn Behav Neurol. 2010 Sep;23(3):152-8. doi: 10.1097/WNN.0b013e3181e078de.
- Rosenthal E, Brennan L, Xie S, Hurtig H, Milber J, Weintraub D, Karlawish J, Siderowf A. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord. 2010 Jul 15;25(9):1170-6. doi: 10.1002/mds.23073.
- Scholtissen B, Verhey FR, Adam JJ, Weber W, Leentjens AF. Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Clin Neuropharmacol. 2006 Sep-Oct;29(5):276-85.
- Timmann D, Daum I. How consistent are cognitive impairments in patients with cerebellar disorders? Behav Neurol. 2010;23(1-2):81-100. doi: 10.3233/BEN-2010-0271. Review.
- 2011-TevAzi